ArticleCancer discovery2022
An
Open access · hybridAbstract read
In one paragraph
Article in Cancer discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
7.7field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 76 citations in OpenAlex.
- Genome-wide CRISPR screens identify an RXR-MYLIP-LDLR axis regulating BH3 mimetic sensitivity in peripheral T-cell lymphomas.Oncogene · 2026Article
- Non-genetic remodeling drives leukemia propagation and reveals actionable vulnerabilities in acute myeloid leukemia.Cell reports. Medicine · 2026Article
- Patient-Derived Organoid-Based CRISPR Screens in Cancer Research: Applications, Advances, and Challenges.Cancer medicine · 2026Review
- Context-dependent synthetic lethality - an emerging precision therapeutic approach.Nature reviews. Cancer · 2026Review
- The benchmarking and application of tag-degraders in vivo to validate therapeutic targets.Nature communications · 2026Article
- Degron models: a toolbox for rapid in vivo depletion of essential proteins regulating mRNA metabolism.Communications biology · 2026Article
- CRISPR-based functional genomics for dissecting therapeutic dependency in primary acute myeloid leukemia samples.Molecular cell · 2026Article
- Harnessing PDX and PDX 2.0: the next-generation paradigm for precision oncology and translational breakthroughs.Molecular cancer · 2026Review
- Article
- Review
- How to drug a leukemic stem cell: deciphering heterogeneity for better specificity.Blood neoplasia · 2025Review
- CRISPR Technology in Disease Management: An Updated Review of Clinical Translation and Therapeutic Potential.Cell proliferation · 2025Article
- Recent advances in drug delivery and treatment strategies for acute myeloid leukemia.International journal of pharmaceutics · 2025Review
- Targeting the BCL2 Family: Advances and Challenges in BH3 Mimetic-Based Therapies.International journal of molecular sciences · 2025Review
- Targeting the MARCH5-MFN2 axis to enhance mitochondrial fusion and sensitize multiple myeloma cells to venetoclax.Journal of translational medicine · 2025Article
- Riboflavin drives nucleotide biosynthesis and iron-sulfur metabolism to promote acute myeloid leukemia.bioRxiv : the preprint server for biology · 2025Article
- PDX models for functional precision oncology and discovery science.Nature reviews. Cancer · 2025Review
- Finding a needle in a haystack: functional screening for novel targets in cancer immunology and immunotherapies.Oncogene · 2025Review
- The E3 ubiquitin ligase MARCH5 promotes mitochondrial fusion and cell-cycle progression in acute myeloid leukemia.Blood advances · 2025Article
- Mitochondrial Dynamics in Blood Cancer Development and Progression.Current pharmacology reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 4 institutions in 2 countries.
Shan LinDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts.ORCID 0000-0002-9699-0250
Clément Larrue *Translational Research Centre in Onco-hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Nastassja K Scheidegger *Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts.ORCID 0000-0002-3091-2970
Bo Kyung A SeongDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts.ORCID 0000-0002-1398-6230
Neekesh V DhariaDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts.ORCID 0000-0001-5048-067X
Miljan KuljaninDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Caroline S WechslerDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts.
Guillaume KugenerThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts.ORCID 0000-0002-4697-2847
Amanda L RobichaudDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts.
Amy Saur ConwayDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts.
Thelma MashakaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Sarah MoucheTranslational Research Centre in Onco-hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Biniam AdaneDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts.
Jeremy A RyanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-3327-1283
Joseph D ManciasDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-0692-3717
Scott T YoungerThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
Federica PiccioniThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts.ORCID 0000-0003-1210-3210
Lynn H LeeDivision of Oncology, Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.ORCID 0000-0002-2898-6196
Mark WunderlichDivision of Experimental Hematology and Cancer Biology, Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.ORCID 0000-0002-2166-5146
Anthony LetaiThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts.ORCID 0000-0002-1993-9013
Jérôme TamburiniTranslational Research Centre in Onco-hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Kimberly StegmaierDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts. Kimberly_stegmaier@dfci.harvard.edu.
Broad Institute · USDana-Farber Cancer Institute · USUniversity of Geneva · CHCincinnati Children's Hospital Medical Center · US
Funding
TYROSINE KINASE ONCOGENESIS IN MYELOID LEUKEMIAP01CA066996 · NCI · DANA-FARBER CANCER INSTITUTE · PI DANIEL J DEANGELO · 1996 to 2026
$52.5MTargeting SYK Kinase in AMLP50CA206963 · NCI · DANA-FARBER CANCER INST · PI ASTER, JON C. · 2017 to 2021
$10.6MIntegrating Transforming Approaches to Identify and Target New Vulnerabilities in CancerR35CA210030 · NCI · DANA-FARBER CANCER INST · PI STEGMAIER, KIMBERLY · 2016 to 2022
$7.3MTherapeutic insights through patient derived leukemia xenograftsR50CA211404 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI Mark Wunderlich · 2016 to 2026
$1.9MSH800 Cell SorterS10OD023410 · OD · CINCINNATI CHILDRENS HOSP MED CTR · PI THORNTON, SHERRY L · 2017 to 2017
$318kCharacterizing the role of MARCH5 in apoptosis regulation in acute myeloid leukemiaK99CA263161 · NCI · DANA-FARBER CANCER INST · PI LIN, SHAN · 2021 to 2022
$272kNCI NIH HHS K99 CA263161NCI NIH HHS P01 CA066996NCI NIH HHS P50 CA206963NCI NIH HHS R35 CA210030NCI NIH HHS R50 CA211404NIH HHS S10 OD023410
Abstract
CRISPR-Cas9-based genetic screens have successfully identified cell type-dependent liabilities in cancer, including acute myeloid leukemia (AML), a devastating hematologic malignancy with poor overall survival. Because most of these screens have been performed
Indexed as
CRISPR-Cas SystemsPrecision MedicineXenograft Model Antitumor AssaysAnimalsAntineoplastic AgentsHumansLeukemia, Myeloid, AcuteAntineoplastic Agents
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.